Blood p-tau217 level linked to later mild cognitive impairment in healthy adults
A JAMA study reports that blood p-tau217 levels predicted mild cognitive impairment years later in people without cognitive deficits at the start. The finding is still under research.
Source: Blood p-tau217 level linked to later mild cognitive impairment in healthy adults (jamanetwork.com). Summary written with AI from the source and reviewed by rules; read the original.
What the research shows
A study published in JAMA reports that blood levels of p-tau217 predicted mild cognitive impairment years later in people who, at the start, showed no cognitive deficit. According to the article that reports the study, the result is an independent replication of earlier research, meaning another group found a pattern similar to studies already published.
P-tau217 is a form of protein that is being studied as a marker of brain changes associated with Alzheimer's disease. Mild cognitive impairment is an intermediate stage between expected aging and dementia, and not everyone with it develops dementia. An association does not mean a test can predict with certainty what will happen to a given person. The article itself notes that the clinical use of this blood test is still under study.
What it means
The result suggests that blood p-tau217 may help researchers identify early signs of risk for memory decline. It is not yet clear how useful this marker is for individual decisions, or how it performs in different populations.
How to read it with care
This result does not replace a medical consultation. Anyone with questions about memory or testing should talk to a doctor or another qualified health professional, who can assess their individual situation.